Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma
- PMID: 34319130
- PMCID: PMC8386466
- DOI: 10.1128/mSphere.00244-21
Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma
Abstract
Recent studies have shown that persistent SARS-CoV-2 infections in immunocompromised patients can trigger the accumulation of an unusual high number of mutations with potential relevance at both biological and epidemiological levels. Here, we report a case of an immunocompromised patient (non-Hodgkin lymphoma patient under immunosuppressive therapy) with a persistent SARS-CoV-2 infection (marked by intermittent positivity) over at least 6 months. Viral genome sequencing was performed at days 1, 164, and 171 to evaluate SARS-CoV-2 evolution. Among the 15 single-nucleotide polymorphisms (SNPs) (11 leading to amino acid alterations) and 3 deletions accumulated during this long-term infection, four amino acid changes (V3G, S50L, N87S, and A222V) and two deletions (18-30del and 141-144del) occurred in the virus Spike protein. Although no convalescent plasma therapy was administered, some of the detected mutations have been independently reported in other chronically infected individuals, which supports a scenario of convergent adaptive evolution. This study shows that it is of the utmost relevance to monitor the SARS-CoV-2 evolution in immunocompromised individuals, not only to identify novel potentially adaptive mutations, but also to mitigate the risk of introducing "hyper-evolved" variants in the community. IMPORTANCE Tracking the within-patient evolution of SARS-CoV-2 is key to understanding how this pandemic virus shapes its genome toward immune evasion and survival. In the present study, by monitoring a long-term COVID-19 immunocompromised patient, we observed the concurrent emergence of mutations potentially associated with immune evasion and/or enhanced transmission, mostly targeting the SARS-CoV-2 key host-interacting protein and antigen. These findings show that the frequent oscillation in the immune status in immunocompromised individuals can trigger an accelerated virus evolution, thus consolidating this study model as an accelerated pathway to better understand SARS-CoV-2 adaptive traits and anticipate the emergence of variants of concern.
Keywords: SARS-CoV-2; convergent evolution; genome sequencing; immunocompromised host; long-term infection.
Figures

Similar articles
-
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21. Epub 2021 Aug 25. mSphere. 2021. PMID: 34431691 Free PMC article.
-
SARS-CoV-2 Variants from Long-Term, Persistently Infected Immunocompromised Patients Have Altered Syncytia Formation, Temperature-Dependent Replication, and Serum Neutralizing Antibody Escape.Viruses. 2024 Sep 9;16(9):1436. doi: 10.3390/v16091436. Viruses. 2024. PMID: 39339912 Free PMC article.
-
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29. Nature. 2021. PMID: 33780970 Free PMC article.
-
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.Front Immunol. 2020 Aug 7;11:1949. doi: 10.3389/fimmu.2020.01949. eCollection 2020. Front Immunol. 2020. PMID: 32849654 Free PMC article. Review.
-
SARS-CoV-2: The Interplay Between Evolution and Host Immunity.Annu Rev Immunol. 2025 Apr;43(1):29-55. doi: 10.1146/annurev-immunol-083122-043054. Epub 2024 Dec 20. Annu Rev Immunol. 2025. PMID: 39705164 Review.
Cited by
-
Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient.Viruses. 2023 Jan 19;15(2):291. doi: 10.3390/v15020291. Viruses. 2023. PMID: 36851504 Free PMC article.
-
Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera.Sci Rep. 2022 Jul 21;12(1):12479. doi: 10.1038/s41598-022-16533-4. Sci Rep. 2022. PMID: 35864211 Free PMC article.
-
Variable rates of SARS-CoV-2 evolution in chronic infections.PLoS Pathog. 2025 Apr 28;21(4):e1013109. doi: 10.1371/journal.ppat.1013109. eCollection 2025 Apr. PLoS Pathog. 2025. PMID: 40294077 Free PMC article.
-
Evolutionary Mechanisms of the Emergence of the Variants of Concern of SARS-CoV-2.Viruses. 2025 Jan 30;17(2):197. doi: 10.3390/v17020197. Viruses. 2025. PMID: 40006952 Free PMC article. Review.
-
SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing.BMJ Case Rep. 2023 Dec 9;16(12):e255255. doi: 10.1136/bcr-2023-255255. BMJ Case Rep. 2023. PMID: 38087481 Free PMC article.
References
-
- Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo H-H, Boucau J, Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY-T, Desjardins M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ. 2020. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 383:2291–2293. doi:10.1056/NEJMc2031364. - DOI - PMC - PubMed
-
- Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, Roberts DJ, Chandra A, Temperton N, Sharrocks K, Blane E, Modis Y, Leigh KE, Briggs JAG, van Gils MJ, Smith KGC, Bradley JR, Smith C, Doffinger R, Ceron-Gutierrez L, Barcenas-Morales G, Pollock DD, Goldstein RA, Smielewska A, Skittrall JP, Gouliouris T, Goodfellow IG, Gkrania-Klotsas E, Illingworth CJR, McCoy LE, Gupta RK, The CITIID-NIHR BioResource COVID-19 Collaboration . 2021. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592:277–282. doi:10.1038/s41586-021-03291-y. - DOI - PMC - PubMed
-
- Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, Barbian K, Judson SD, Fischer ER, Martens C, Bowden TA, de Wit E, Riedo FX, Munster VJ. 2020. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183:1901–1912. doi:10.1016/j.cell.2020.10.049. - DOI - PMC - PubMed
-
- Bazykin GA, Stanevich O, Danilenko D, Fadeev A, Komissarova K, Ivanova A, et al. .2020. Emergence of Y453F and Δ69-70HV mutations in a lymphoma patient with long-term COVID-19. https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-....
-
- Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. 2020. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369:1014–1018. doi:10.1126/science.abd0831. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous